Published in Transplantation on May 01, 1992
Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73
The innate immune response in ischemic acute kidney injury. Clin Immunol (2008) 1.98
Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol (1993) 1.17
Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model. Clin Exp Immunol (2012) 0.78
Effect of ONO-4057 and tacrolimus on ischemia-reperfusion injury of the liver. World J Gastroenterol (2009) 0.77
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem (1988) 5.75
Cyclosporine. N Engl J Med (1989) 5.67
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol (1981) 4.31
Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest (1984) 2.88
Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am J Physiol (1987) 2.75
The role of cell swelling in ischemic renal damage and the protective effect of hypertonic solute. J Clin Invest (1972) 2.38
Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol (1983) 2.37
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun (1986) 2.27
Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01
Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol (1986) 1.99
Postischemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol (1989) 1.77
Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods (1986) 1.77
Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest (1989) 1.73
Cyclosporine nephrotoxicity. Kidney Int (1986) 1.44
Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med (1982) 1.30
The effect of FK 506 and CyA on the Lewis rat renal ischemia model. Transplant Proc (1990) 1.28
Neutrophil-mediated vascular injury. Acta Med Scand Suppl (1987) 1.26
Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc (1990) 1.14
A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med (1983) 1.14
Neutrophils accentuate ischemia-reperfusion injury in isolated perfused rat kidneys. Am J Physiol (1988) 1.12
Effects of mannitol on the postischemic kidney. Biochemical, functional, and morphologic assessments. Lab Invest (1985) 1.05
FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology (1991) 1.05
Oxidant stress following renal ischemia: changes in the glutathione redox ratio. Kidney Int (1988) 1.01
Role of neutrophils in hemorrhagic shock-induced gastric mucosal injury in the rat. Gastroenterology (1987) 0.99
Degree and time sequence of hypothermic protection against experimental ischemic acute renal failure. Circ Res (1989) 0.97
FK 506 ameliorates the hepatic injury associated with ischemia. Life Sci (1990) 0.97
The contribution of vascular obstruction to the functional defect that follows renal ischemia. Kidney Int (1987) 0.95
Granulocytes and no-reflow phenomenon in irreversible hemorrhagic shock. Circ Res (1988) 0.93
Tumor necrosis factor-enhanced leukotriene B4 generation and chemotaxis in human neutrophils. Arch Surg (1988) 0.93
Cellular calcium in ischemic acute renal failure: role of calcium entry blockers. Kidney Int (1987) 0.93
Protective effect of FK 506 against hepatic ischemia in rats. Transplant Proc (1991) 0.90
Cyclosporine and the ischemic rat kidney. Transplantation (1986) 0.87
Red cell trapping after ischemia and long-term kidney damage. Influence of hematocrit. Kidney Int (1990) 0.86
Renal capillary permeability and intravascular red cell aggregation after ischaemia. I. Effects of xanthine oxidase activity. Acta Physiol Scand (1987) 0.82
Effects of neutrophil granulocytes on the inulin barrier of renal tubular epithelium after ischaemic damage. Acta Physiol Scand (1988) 0.82
Effect of cyclosporine upon the function of ischemically damaged kidneys in the rat. Transplantation (1986) 0.82
Postischemic ATP levels predict hepatic function 24 hours following ischemia in the rat. Experientia (1988) 0.80
Protection of the kidney against ischemic injury by inhibition of 5'-nucleotidase. Am J Physiol (1989) 0.80
Prevention of acute cyclosporine nephrotoxicity by atrial natriuretic factor after ischemia in the rat. Transplantation (1989) 0.80
Cyclosporine and experimental renal ischemic injury. Transplantation (1986) 0.80
Platelet-activating factor and cellular immune responses. Immunol Today (1987) 0.79
Brief intermittent reperfusion during renal ischemia: effects on adenine nucleotides, oxidant stress, and the severity of renal failure. J Lab Clin Med (1990) 0.77
Effects of cold ischemia and reperfusion on trapping of erythrocytes in the rat kidney. Transpl Int (1988) 0.77
Prevention of ischaemic acute renal failure with superoxide dismutase and sucrose. Acta Physiol Scand (1987) 0.76
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science (2000) 5.85
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION. Surg Res Commun (1987) 4.68
Liver transplantation (1). N Engl J Med (1989) 4.53
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther (2000) 2.96
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Liver transplantation (2). N Engl J Med (1989) 2.93
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol (1992) 2.33
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Left hepatic trisegmentectomy. Surg Gynecol Obstet (1982) 2.16
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01
Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82
Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet (1997) 1.76
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Factors in the Development of Liver Transplantation. Transplant Proc (1985) 1.74
Hepatic artery in liver transplantation. Transplant Proc (1987) 1.73
Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg (1998) 1.72
Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med (2000) 1.72
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. Transplant Proc (1990) 1.71
Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation (1991) 1.71